Andrew Weickhardt

Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer.

Andrew J Weickhardt, David K Lau, Margeaux Hodgson-Garms, Austen Lavis, Laura J Jenkins, Natalia Vukelic, Paul Ioannidis, Ian Y Luk, John M Mariadason

Journal article  |  2022  |  BMC Cancer

BACKGROUND: Mutations and fusions in Fibroblast Growth Factor Receptor 3 (FGFR3) occur in 10-20% of metastatic urothelial carcinom..

Real-world first-line systemic therapy patterns in metastatic castration-resistant prostate cancer.

Angelyn Anton, Sruti Pillai, Marie Christine Semira, Shirley Wong, Julia Shapiro, Andrew Weickhardt, Arun Azad, Edmond M Kwan, Lavinia Spain, Ashray Gunjur, Javier Torres, Phillip Parente, Francis Parnis, Jeffrey Goh, Olivia Baenziger, Peter Gibbs, Ben Tran

Journal article  |  2022  |  BJUI Compass

INTRODUCTION: Several systemic therapies have demonstrated a survival advantage in metastatic castration resistant prostate cancer..

Adjuvant therapies for non-muscle-invasive bladder cancer: advances during BCG shortage

Adithya Balasubramanian, Ashray Gunjur, Andrew Weickhardt, Nathan Papa, Damien Bolton, Nathan Lawrentschuk, Marlon Perera

Journal article  |  2022  |  WORLD JOURNAL OF UROLOGY

Non-muscle-invasive bladder cancer (NMIBC) represents a significant global therapeutic challenge, particularly in the era of Bacil..

VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer

Fiona Chionh, Val Gebski, Sheren J Al-Obaidi, Jennifer K Mooi, Maressa A Bruhn, Chee K Lee, Anderly C Chueh, David S Williams, Andrew J Weickhardt, Kate Wilson, Andrew M Scott, John Simes, Jennifer E Hardingham, Timothy J Price, John M Mariadason, Niall C Tebbutt

Journal article  |  2022  |  SCIENTIFIC REPORTS

The phase III MAX clinical trial randomised patients with metastatic colorectal cancer (mCRC) to receive first-line capecitabine c..

Real-world incidence of symptomatic skeletal events and bone-modifying agent use in castration-resistant prostate cancer- an Australian multi-centre observational study

Angelyn Anton, Shirley Wong, Julia Shapiro, Andrew Weickhardt, Arun Azad, Edmond M Kwan, Lavinia Spain, Ashray Gunjur, Javier Torres, Phillip Parente, Francis Parnis, Jeffrey Goh, Marie C Semira, Peter Gibbs, Ben Tran, Carmel Pezaro

Journal article  |  2021  |  EUROPEAN JOURNAL OF CANCER

INTRODUCTION: Bone metastases occur frequently in castration-resistant prostate cancer (CRPC) and may lead to skeletal-related eve..

Real-world use of first-generation antiandrogens: impact on patient outcomes and subsequent therapies in metastatic castration-resistant prostate cancer

Richard Kelly, Angelyn Anton, Shirley Wong, Julia Shapiro, Andrew Weickhardt, Arun Azad, Edmond Michael Kwan, Lavinia Spain, Arun Muthusamy, Javier Torres, Phillip Parente, Francis Parnis, Jeffrey Goh, Anthony Joshua, David Pook, Olivia Baenziger, Peter Gibbs, Ben Tran

Journal article  |  2021  |  BJU INTERNATIONAL

OBJECTIVES: To investigate the recent real-world use of first-generation antiandrogens (FGAs) in metastatic castration-resistant p..

Changes in prescribing habits for the treatment of metastatic renal clear cell carcinoma (mRCC) in Australia

Adithya Balasubramanian, Liang Qu, Andrew Weickhardt, Damien Bolton, Marlon Perera

Journal article  |  2021  |  INTERNAL MEDICINE JOURNAL

The availability of efficacious systemic therapies for metastatic clear cell renal cell carcinoma has heralded improved survival f..

Rapid Resistance of FGFR-driven Gastric Cancers to Regorafenib and Targeted FGFR Inhibitors can be Overcome by Parallel Inhibition of MEK

David K Lau, Ian Y Luk, Laura J Jenkins, Andrew Martin, David S Williams, Kael L Schoffer, Fiona Chionh, Michael Buchert, Katrin Sjoquist, Alex Boussioutas, Sarah A Hayes, Matthias Ernst, Andrew J Weickhardt, Nick Pavlakis, Niall C Tebbutt, John M Mariadason

Journal article  |  2021  |  MOLECULAR CANCER THERAPEUTICS

Amplification or overexpression of the FGFR family of receptor tyrosine kinases occurs in a significant proportion of gastric canc..

[Lu-177]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

Michael S Hofman, Louise Emmett, Shahneen Sandhu, Amir Iravani, Anthony M Joshua, Jeffrey C Goh, David A Pattison, Thean Hsiang Tan, Ian D Kirkwood, Siobhan Ng, Roslyn J Francis, Craig Gedye, Natalie K Rutherford, Andrew Weickhardt, Andrew M Scott, Sze-Ting Lee, Edmond M Kwan, Arun A Azad, Shakher Ramdave, Andrew D Redfern, et al.

Journal article  |  2021  |  LANCET

BACKGROUND: Lutetium-177 [177Lu]Lu-PSMA-617 is a radiolabelled small molecule that delivers β radiation to cells expressing prosta..

Treatment outcomes for patients with metastatic castrate-resistant prostate cancer following docetaxel for hormone-sensitive disease

Andrew Schmidt, Angelyn Anton, Julia Shapiro, Shirley Wong, Arun Azad, Edmond Kwan, Lavinia Spain, Arun Muthusamy, Javier Torres, Phillip Parente, Francis Parnis, Jeffrey Goh, Anthony M Joshua, David Pook, Peter Gibbs, Ben Tran, Andrew Weickhardt

Journal article  |  2020  |  ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY

AIM: Optimal treatment for newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) has evolved, with many patients de..